title: Tenofovir disoproxil fumarate, emtricitabine, and efavirenz compared with zidovudine/lamivudine and efavirenz in treatment-naive patients: 144-week analysis.
abstract: BACKGROUND
  As antiretroviral regimens for the treatment of HIV infection improve, trials providing data on long-term follow-up are increasingly important.
  
  
  METHODS
  A regimen of tenofovir disoproxil fumarate (TDF), emtricitabine (FTC), and efavirenz (EFV) demonstrated superior virologic, immunologic and morphologic effects compared with a regimen of fixed-dose zidovudine/lamivudine (ZDV/3TC) and EFV through 96 weeks in a randomized open-label trial. After 96 weeks, patients on TDF + FTC transitioned to fixed-dose combination TDF/FTC.
  
  
  RESULTS
  Through 144 weeks, significantly more patients in the TDF/FTC arm reached and maintained an HIV RNA level <400 copies/mL (71% receiving TDF/FTC and EFV vs. 58% receiving ZDV/3TC and EFV; P = 0.004), with a trend toward greater CD4 cell increase in the TDF/FTC arm (312 vs. 271 cells/mm; P = 0.09). Over 144 weeks of follow-up, more patients in the ZDV/3TC arm discontinued therapy because of adverse events (11% vs. 5%; P = 0.01) and no patients discontinued because of renal events. Patients in the ZDV/3TC arm had significantly less limb fat than patients in the TDF/FTC arm (5.4 vs. 7.9 kg; P < 0.001) at 144 weeks.
  
  
  CONCLUSIONS
  Cumulative results from 3 years of follow-up suggest that a regimen of TDF/FTC and EFV demonstrates superior durability of viral load suppression and an improved safety and morphologic profile compared with ZDV/3TC and EFV.
authors.affiliation: Internal Medicine Service, Hospital de La Paz, Madrid, Spain.
authors.forename: Jose R
authors.initials: JR
authors.lastname: Arribas
authors.forename: Anton L
authors.initials: AL
authors.lastname: Pozniak
authors.forename: Joel E
authors.initials: JE
authors.lastname: Gallant
authors.forename: Edwin
authors.initials: E
authors.lastname: Dejesus
authors.forename: Brian
authors.initials: B
authors.lastname: Gazzard
authors.forename: Rafael E
authors.initials: RE
authors.lastname: Campo
authors.forename: Shan-Shan
authors.initials: SS
authors.lastname: Chen
authors.forename: Damian
authors.initials: D
authors.lastname: McColl
authors.forename: Charles B
authors.initials: CB
authors.lastname: Holmes
authors.forename: Jeffrey
authors.initials: J
authors.lastname: Enejosa
authors.forename: John J
authors.initials: JJ
authors.lastname: Toole
authors.forename: Andrew K
authors.initials: AK
authors.lastname: Cheng
mesh_terms: D000225:Adenine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000328:Adult; D000480:Alkynes; D048588:Benzoxazines / Q000008:administration & dosage / Q000627:therapeutic use*; D003521:Cyclopropanes; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D024882:Drug Resistance, Viral; D004359:Drug Therapy, Combination; D000068679:Emtricitabine; D005260:Female; D015658:HIV Infections / Q000188:drug therapy*; D006801:Humans; D019259:Lamivudine / Q000008:administration & dosage / Q000627:therapeutic use*; D008297:Male; D063065:Organophosphonates / Q000008:administration & dosage / Q000627:therapeutic use*; D018894:Reverse Transcriptase Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D000068698:Tenofovir; D015215:Zidovudine / Q000008:administration & dosage / Q000627:therapeutic use*
chemical_list: D000480:Alkynes; D048588:Benzoxazines; D003521:Cyclopropanes; D063065:Organophosphonates; D018894:Reverse Transcriptase Inhibitors; D003841:Deoxycytidine; D019259:Lamivudine; D015215:Zidovudine; D000068698:Tenofovir; D000068679:Emtricitabine; D000225:Adenine; C098320:efavirenz